论文部分内容阅读
目的对曲妥珠单抗(trastuzumab,TRA)辅助治疗早期人表皮生长因子受体2(HER2)阳性乳腺癌的应用情况进行概述。方法参考国内外大量文献,对曲妥珠单抗的药理学性质及其辅助治疗早期人表皮生长因子受体2阳性乳腺癌的临床疗效和不良反应进行阐述。结果联合曲妥珠单抗治疗能持续延长早期人表皮生长因子受体2阳性乳腺癌患者的无病生存期和总体生存期;序贯曲妥珠单抗治疗的效果有好有坏;曲妥珠单抗辅助治疗的一般耐受性良好;存在对心脏的不良影响,然而其大多可逆。结论曲妥珠单抗是早期人表皮生长因子受体2阳性乳癌患者辅助治疗的重要组成部分。
Objective To summarize the application of trastuzumab (TRA) in adjuvant treatment of early human epidermal growth factor receptor 2 (HER2) positive breast cancer. Methods With reference to a large number of literatures at home and abroad, the pharmacological properties of trastuzumab and its clinical efficacy and side effects in adjuvant treatment of early-stage human epidermal growth factor receptor-2 positive breast cancer were expounded. Results The combination of trastuzumab treatment can prolong the disease-free survival and overall survival of patients with early-stage human epidermal growth factor receptor-2 positive breast cancer. The effect of sequential trastuzumab treatment is good or bad; The general tolerability of Bead’s adjuvant therapy is good; there are adverse effects on the heart, however, which are mostly reversible. Conclusion Trastuzumab is an important part of the adjuvant therapy for patients with early-stage human epidermal growth factor receptor-2 positive breast cancer.